CEL-SCI Corporation (CVM)
NYSEAMERICAN: CVM · IEX Real-Time Price · USD
1.310
+0.100 (8.26%)
Jul 26, 2024, 4:00 PM EDT - Market closed
CEL-SCI Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
43
Market Cap
70.95M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
SHL Telemedicine | 57.08M |
Gritstone bio | 15.65M |
Prenetics Global | 10.61M |
Milestone Scientific | 9.48M |
T2 Biosystems | 7.18M |
InspireMD | 6.48M |
Ovid Therapeutics | 473.54K |
CVM News
- 20 hours ago - CEL-SCI Announces Pricing of $10.8 Million Offering - Business Wire
- 23 hours ago - CEL-SCI's Phase 3 Population Analysis for Upcoming Confirmatory Registration Study in Head & Neck Cancer Demonstrates Well Balanced Patient Population, Confidence in Clinical Results - Business Wire
- 18 days ago - CEL-SCI Appoints Robert Watson as Chairperson of the Board - Business Wire
- 5 weeks ago - CEL-SCI Presents Head & Neck Cancer Data at Iddst Annual Congress in Budapest: Risk of Death Cut in Half for Patients Treated With Multikine in the Target Population - Business Wire
- 7 weeks ago - Dr. Giovanni Selvaggi, Who Has Brought Several Oncology Drugs to Market, Joins CEL-SCI as Clinical Advisor - Business Wire
- 2 months ago - CEL-SCI Corporation Reports Second Quarter Fiscal 2024 Financial Results - Business Wire
- 2 months ago - CEL-SCI Receives FDA Go-Ahead for Its Confirmatory Study of Multikine in the Treatment of Head & Neck Cancer - Business Wire
- 3 months ago - CEL-SCI Appoints Mario Gobbo to Its Board of Directors - Business Wire